Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs State Street SPDR S&P Homebuilders ETF (XHB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs State Street SPDR S&P Homebuilders ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $287.91 (market cap $39.89B), while State Street SPDR S&P Homebuilders ETF trades at $107.22. The key difference: State Street SPDR S&P Homebuilders ETF is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | XHB | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $491.22 | $121.36 |
52-Week Low | $278.09 | $94.86 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
XHB trades at $108.61, up 0.93% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The ETF faces mixed housing data with June existing home sales declining 2.4% month-over-month amid record prices and mortgage rate pressures (CNBC, 2026-07-09). Key support sits at $104, while resistance is near $109. Financial ratios are unavailable in the provided data, limiting fundamental assessment.
Outlook remains cautious due to technical weakness and housing market volatility. Risks include sustained high mortgage rates and inventory constraints, though some sentiment improvement in May (CNBC, 2026-05-18) offers hope. Investors should monitor upcoming earnings from underlying holdings for clarity on profitability trends amid economic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About State Street SPDR S&P Homebuilders ETF
XHB invests in the U.S. homebuilding industry and related sectors. It provides equal-weighted exposure to homebuilders, building products, and home improvement retailers like Home Depot, Lowe's, and Builders FirstSource.
Read more on XHB →
